broad_id
string | depmap_id
string | ccle_name
string | screen_id
string | upper_limit
int64 | lower_limit
float64 | slope
float64 | r2
float64 | auc
float64 | ec50
float64 | ic50
float64 | name
string | moa
string | target
string | disease.area
string | indication
string | smiles
string | phase
string | passed_str_profiling
bool | row_name
string |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
BRD-K38527262-300-01-0 | ACH-000990 | HEC108_ENDOMETRIUM | MTS010 | 1 | 0.192595 | 2.778834 | 0.700811 | 0.913857 | 3.337395 | 3.97587 | atiprimod | JAK inhibitor, STAT inhibitor | JAK2, STAT3 | null | null | CCCC1(CCC)CCC2(CCN(CCCN(CC)CC)C2)CC1 | Phase 2 | true | ACH-000990 |
BRD-K38852836-001-02-1 | ACH-000990 | HEC108_ENDOMETRIUM | MTS010 | 1 | 1.101171 | -0.035847 | -0.055549 | 1 | 717,961.374991 | null | ganetespib | HSP inhibitor | HSP90AA1 | null | null | CC(C)c1cc(-c2n[nH]c(=O)n2-c2ccc3n(C)ccc3c2)c(O)cc1O | Phase 3 | true | ACH-000990 |
BRD-K42495768-001-01-7 | ACH-000990 | HEC108_ENDOMETRIUM | MTS010 | 1 | 0.773796 | 2.073733 | 0.394728 | 0.937338 | 0.681187 | null | tasisulam | apoptosis stimulant | null | null | null | Clc1ccc(C(=O)NS(=O)(=O)c2ccc(Br)s2)c(Cl)c1 | Phase 3 | true | ACH-000990 |
BRD-K42805893-001-04-9 | ACH-000990 | HEC108_ENDOMETRIUM | MTS010 | 1 | 0.788838 | 0.318972 | 0.03725 | 0.859524 | 0.0061 | null | osimertinib | EGFR inhibitor | EGFR | oncology | non-small cell lung cancer (NSCLC) | COc1cc(N(C)CCN(C)C)c(NC(=O)C=C)cc1Nc1nccc(n1)-c1cn(C)c2ccccc12 | Launched | true | ACH-000990 |
BRD-K42828737-001-03-3 | ACH-000990 | HEC108_ENDOMETRIUM | MTS010 | 1 | 0.808009 | 0.646758 | -0.210069 | 0.903061 | 0.074142 | null | sunitinib | FLT3 inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor | CSF1R, FGFR1, FLT1, FLT3, FLT4, KDR, KIT, PDGFRA, PDGFRB, RET | oncology | gastrointestinal stromal tumors (GIST), renal cell carcinoma (RCC), neuroendocrine tumors of pancreatic origin (PNET) | CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C, CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C, CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C, CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C | Launched | true | ACH-000990 |
BRD-K42898655-001-01-8 | ACH-000990 | HEC108_ENDOMETRIUM | MTS010 | 1 | 1.124003 | 0.03658 | -0.00331 | 1 | 0.011066 | null | temsirolimus | mTOR inhibitor | MTOR | oncology | renal cell carcinoma (RCC) | CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@@H]1OC(=O)C(C)(CO)CO | Launched | true | ACH-000990 |
BRD-K43389675-001-02-1 | ACH-000990 | HEC108_ENDOMETRIUM | MTS010 | 1 | -0.013721 | 1.154311 | 0.911815 | 0.734005 | 0.821187 | 0.802145 | daunorubicin | RNA synthesis inhibitor, topoisomerase inhibitor | TOP2A, TOP2B | hematologic malignancy | acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL) | COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O | Launched | true | ACH-000990 |
BRD-K44227013-001-06-4 | ACH-000990 | HEC108_ENDOMETRIUM | MTS010 | 1 | 0.644925 | 0.10619 | 0.047833 | 0.830141 | 0.179667 | null | ponatinib | Bcr-Abl kinase inhibitor, FLT3 inhibitor, PDGFR tyrosine kinase receptor inhibitor | ABL1, BCR, FGFR1, FGFR2, FGFR3, FGFR4, FLT3, KDR, KIT, LCK, LYN, PDGFRA, RET, SRC, TEK | hematologic malignancy | chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL) | CN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(c3)C#Cc3cnc4cccnn34)cc2C(F)(F)F)CC1, CN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(c3)C#Cc3cnc4cccnn34)cc2C(F)(F)F)CC1 | Launched | true | ACH-000990 |
BRD-K44408410-001-17-6 | ACH-000990 | HEC108_ENDOMETRIUM | MTS010 | 1 | 1.059354 | 0.392051 | -0.049599 | 1 | 0.004893 | null | 2-methoxyestradiol | hypoxia inducible factor inhibitor | COMT, CYP19A1, CYP1A1, CYP1B1, HIF1A, TUBB | null | null | COc1cc2[C@H]3CC[C@]4(C)[C@@H](O)CC[C@H]4[C@@H]3CCc2cc1O, COc1cc2[C@H]3CC[C@]4(C)[C@@H](O)CC[C@H]4[C@@H]3CCc2cc1O, COc1cc2[C@H]3CC[C@]4(C)[C@@H](O)CC[C@H]4[C@@H]3CCc2cc1O | Phase 2 | true | ACH-000990 |
BRD-K44827188-001-06-0 | ACH-000990 | HEC108_ENDOMETRIUM | MTS010 | 1 | 0.975312 | -0.016736 | -0.012418 | 0.987824 | 0.015286 | null | vismodegib | hedgehog pathway inhibitor, smoothened receptor antagonist | SMO | oncology | basal cell carcinoma (BCC) | Clc1cc(ccc1C(=O)Nc1ccc(Cl)c(c1)-c1ccccn1)S(C)(=O)=O | Launched | true | ACH-000990 |
BRD-K46386702-001-02-1 | ACH-000990 | HEC108_ENDOMETRIUM | MTS010 | 1 | 1.131003 | 0.791278 | -0.180059 | 1 | 0.301107 | null | ARRY-334543 | EGFR inhibitor | ERBB2 | null | null | C[C@@H]1COC(Nc2ccc3ncnc(Nc4ccc(OCc5nccs5)c(Cl)c4)c3c2)=N1 | Phase 2 | true | ACH-000990 |
BRD-K49328571-001-15-0 | ACH-000990 | HEC108_ENDOMETRIUM | MTS010 | 1 | 0.514792 | 0.300433 | 0.18883 | 0.628383 | 0.000829 | null | dasatinib | Bcr-Abl kinase inhibitor, ephrin inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, src inhibitor, tyrosine kinase inhibitor | ABL1, ABL2, BLK, EPHA2, FGR, FRK, FYN, HCK, KIT, LCK, LYN, PDGFRB, SRC, SRMS, STAT5B, YES1 | hematologic malignancy | chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL) | Cc1nc(Nc2ncc(s2)C(=O)Nc2c(C)cccc2Cl)cc(n1)N1CCN(CCO)CC1, Cc1nc(Nc2ncc(s2)C(=O)Nc2c(C)cccc2Cl)cc(n1)N1CCN(CCO)CC1 | Launched | true | ACH-000990 |
BRD-K49350383-001-14-5 | ACH-000990 | HEC108_ENDOMETRIUM | MTS010 | 1 | 1.015035 | -0.230144 | -0.089796 | 1 | 0.30403 | null | thioguanine | purine antagonist | IMPDH1, IMPDH2 | hematologic malignancy | acute myeloid leukemia (AML) | Nc1nc2nc[nH]c2c(=S)[nH]1, Nc1nc2nc[nH]c2c(=S)[nH]1, Nc1nc2nc[nH]c2c(=S)[nH]1 | Launched | true | ACH-000990 |
BRD-K50010139-001-01-5 | ACH-000990 | HEC108_ENDOMETRIUM | MTS010 | 1 | 0.741582 | 0.856137 | 0.17009 | 0.895865 | 0.207104 | null | poziotinib | EGFR inhibitor | EGFR, ERBB2, ERBB4 | null | null | COc1cc2ncnc(Nc3ccc(Cl)c(Cl)c3F)c2cc1OC1CCN(CC1)C(=O)C=C, COc1cc2ncnc(Nc3ccc(Cl)c(Cl)c3F)c2cc1OC1CCN(CC1)C(=O)C=C | Phase 2 | true | ACH-000990 |
BRD-K50168500-001-07-9 | ACH-000990 | HEC108_ENDOMETRIUM | MTS010 | 1 | 0.195991 | 0.695875 | 0.774491 | 0.760604 | 0.675006 | 1.37984 | canertinib | EGFR inhibitor | AKT1, EGFR, ERBB2, ERBB4 | null | null | Fc1ccc(Nc2ncnc3cc(OCCCN4CCOCC4)c(NC(=O)C=C)cc23)cc1Cl | Phase 3 | true | ACH-000990 |
BRD-K51313569-001-07-8 | ACH-000990 | HEC108_ENDOMETRIUM | MTS010 | 1 | 0.386082 | 0.514388 | 0.416943 | 0.855156 | 1.984232 | null | palbociclib | CDK inhibitor | CDK4, CDK6 | oncology | breast cancer | CC(=O)c1c(C)c2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n(C2CCCC2)c1=O, CC(=O)c1c(C)c2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n(C2CCCC2)c1=O | Launched | true | ACH-000990 |
BRD-K51791723-003-01-7 | ACH-000990 | HEC108_ENDOMETRIUM | MTS010 | 1 | 0.014935 | 0.924811 | 0.396134 | 0.75795 | 1.043925 | 1.078744 | P276-00 | CDK inhibitor | CDK1, CDK4, CDK9 | null | null | CN1CC[C@H]([C@@H]1CO)c1c(O)cc(O)c2c1oc(cc2=O)-c1ccccc1Cl | Phase 2 | true | ACH-000990 |
BRD-K51967704-001-03-6 | ACH-000990 | HEC108_ENDOMETRIUM | MTS010 | 1 | 1.284314 | 0.235085 | 0.050314 | 1 | 3.675427 | null | BIIB021 | HSP inhibitor | HSP90AA1 | null | null | COc1c(C)cnc(Cn2cnc3c(Cl)nc(N)nc23)c1C, COc1c(C)cnc(Cn2cnc3c(Cl)nc(N)nc23)c1C | Phase 2 | true | ACH-000990 |
BRD-K52313696-001-12-3 | ACH-000990 | HEC108_ENDOMETRIUM | MTS010 | 1 | 0.912335 | 0.150062 | 0.017703 | 0.954335 | 0.043641 | null | tacedinaline | HDAC inhibitor | HDAC1 | null | null | CC(=O)Nc1ccc(cc1)C(=O)Nc1ccccc1N, CC(=O)Nc1ccc(cc1)C(=O)Nc1ccccc1N | Phase 3 | true | ACH-000990 |
BRD-K53414658-001-08-2 | ACH-000990 | HEC108_ENDOMETRIUM | MTS010 | 1 | 0.935379 | 7.443731 | 0.050762 | 0.967899 | 0.080598 | null | tivozanib | VEGFR inhibitor | FLT1, FLT4, KDR, KIT, PDGFRA, PDGFRB | null | null | COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC | Phase 3 | true | ACH-000990 |
BRD-K54256913-001-08-7 | ACH-000990 | HEC108_ENDOMETRIUM | MTS010 | 1 | 0.506703 | 0.247705 | 0.245248 | 0.732151 | 0.035899 | null | MK-1775 | WEE1 kinase inhibitor | WEE1 | null | null | CN1CCN(CC1)c1ccc(Nc2ncc3c(n2)n(-c2cccc(n2)C(C)(C)O)n(CC=C)c3=O)cc1 | Phase 2 | true | ACH-000990 |
BRD-K54997624-001-06-0 | ACH-000990 | HEC108_ENDOMETRIUM | MTS010 | 1 | 1.549897 | 3.665065 | 0.763989 | 1 | 1.510374 | null | alpelisib | PI3K inhibitor | PIK3CA, PIK3CB, PIK3CD, PIK3CG | null | null | Cc1nc(NC(=O)N2CCC[C@H]2C(N)=O)sc1-c1ccnc(c1)C(C)(C)C(F)(F)F | Phase 3 | true | ACH-000990 |
BRD-K55187425-236-05-2 | ACH-000990 | HEC108_ENDOMETRIUM | MTS010 | 1 | 0.828734 | 0.30219 | -0.13719 | 0.93997 | 0.84614 | null | rigosertib | cell cycle inhibitor, PLK inhibitor | PLK1 | null | null | COc1cc(OC)c(\C=C\S(=O)(=O)Cc2ccc(OC)c(NCC(O)=O)c2)c(OC)c1, COc1cc(OC)c(\C=C\S(=O)(=O)Cc2ccc(OC)c(NCC(O)=O)c2)c(OC)c1, COc1cc(OC)c(\C=C\S(=O)(=O)Cc2ccc(OC)c(NCC(O)=O)c2)c(OC)c1 | Phase 3 | true | ACH-000990 |
BRD-K56343971-001-14-8 | ACH-000990 | HEC108_ENDOMETRIUM | MTS010 | 1 | 1.080028 | -0.354998 | -0.104355 | 1 | 0.118451 | null | vemurafenib | RAF inhibitor | BRAF, RAF1 | oncology | melanoma | CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(cc23)-c2ccc(Cl)cc2)c1F, CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(cc23)-c2ccc(Cl)cc2)c1F, CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(cc23)-c2ccc(Cl)cc2)c1F | Launched | true | ACH-000990 |
BRD-K56981171-001-02-8 | ACH-000990 | HEC108_ENDOMETRIUM | MTS010 | 1 | 0.566966 | -0.154528 | -0.402526 | 0.780655 | 0.093217 | null | brigatinib | ALK tyrosine kinase receptor inhibitor, EGFR inhibitor | ALK, EGFR | oncology | non-small cell lung cancer (NSCLC) | COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccccc2P(C)(C)=O)n1)N1CCC(CC1)N1CCN(C)CC1, COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccccc2P(C)(C)=O)n1)N1CCC(CC1)N1CCN(C)CC1 | Launched | true | ACH-000990 |
BRD-K57080016-001-15-9 | ACH-000990 | HEC108_ENDOMETRIUM | MTS010 | 1 | 0.704765 | -0.060965 | 0.01999 | 0.818933 | 159.07004 | null | selumetinib | MEK inhibitor | MAP2K1 | null | null | Cn1cnc2c(F)c(Nc3ccc(Br)cc3Cl)c(cc12)C(=O)NOCCO, Cn1cnc2c(F)c(Nc3ccc(Br)cc3Cl)c(cc12)C(=O)NOCCO | Phase 3 | true | ACH-000990 |
BRD-K57169635-001-04-5 | ACH-000990 | HEC108_ENDOMETRIUM | MTS010 | 1 | -0.152677 | 0.576913 | 0.548408 | 0.747053 | 2.119484 | 1.335459 | dacomitinib | EGFR inhibitor | EGFR, ERBB2, ERBB4 | null | null | COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)\C=C\CN1CCCCC1 | Phase 3 | true | ACH-000990 |
BRD-K58435339-001-03-0 | ACH-000990 | HEC108_ENDOMETRIUM | MTS010 | 1 | 1.269642 | 1.547775 | 0.278306 | 1 | 0.05321 | null | AT13387 | HSP antagonist | HSP90AA1 | null | null | CC(C)c1cc(C(=O)N2Cc3ccc(CN4CCN(C)CC4)cc3C2)c(O)cc1O, CC(C)c1cc(C(=O)N2Cc3ccc(CN4CCN(C)CC4)cc3C2)c(O)cc1O | Phase 2 | true | ACH-000990 |
BRD-K58529924-001-01-5 | ACH-000990 | HEC108_ENDOMETRIUM | MTS010 | 1 | 0.992004 | 0.210726 | -0.036192 | 0.996522 | 0.318583 | null | ONC201 | AKT inhibitor, MAP kinase inhibitor | TNFSF10 | null | null | Cc1ccccc1CN1C2=NCCN2C2=C(CN(Cc3ccccc3)CC2)C1=O | Phase 2 | true | ACH-000990 |
BRD-K58550667-001-08-7 | ACH-000990 | HEC108_ENDOMETRIUM | MTS010 | 1 | 0.619592 | 0.297827 | 0.191597 | 0.82422 | 0.008855 | null | FK-866 | niacinamide phosphoribosyltransferase inhibitor | NAMPT | null | null | O=C(NCCCCC1CCN(CC1)C(=O)c1ccccc1)\C=C\c1cccnc1 | Phase 2 | true | ACH-000990 |
BRD-K59317601-001-05-5 | ACH-000990 | HEC108_ENDOMETRIUM | MTS010 | 1 | 0.419566 | 1.304227 | 0.653861 | 0.697261 | 0.063301 | 0.256946 | MLN0128 | mTOR inhibitor | MTOR, PIK3CA, PIK3CD, PIK3CG | null | null | CC(C)n1nc(-c2ccc3oc(N)nc3c2)c2c(N)ncnc12 | Phase 2 | true | ACH-000990 |
BRD-K59369769-001-22-9 | ACH-000990 | HEC108_ENDOMETRIUM | MTS010 | 1 | 1.038985 | -0.095177 | -0.044934 | 1 | 45.38393 | null | tozasertib | Aurora kinase inhibitor, Bcr-Abl kinase inhibitor, FLT3 inhibitor, JAK inhibitor | AURKA, AURKB, AURKC, LCK | null | null | CN1CCN(CC1)c1cc(Nc2cc(C)[nH]n2)nc(Sc2ccc(NC(=O)C3CC3)cc2)n1, CN1CCN(CC1)c1cc(Nc2cc(C)[nH]n2)nc(Sc2ccc(NC(=O)C3CC3)cc2)n1 | Phase 2 | true | ACH-000990 |
BRD-K60866521-001-07-1 | ACH-000990 | HEC108_ENDOMETRIUM | MTS010 | 1 | 0.831745 | -3.398834 | 0.10954 | 0.910066 | 0.109169 | null | idelalisib | PI3K inhibitor | PIK3CA, PIK3CB, PIK3CD, PIK3CG | hematologic malignancy | chronic lymphocytic leukemia (CLL) | CC[C@H](Nc1ncnc2[nH]cnc12)c1nc2cccc(F)c2c(=O)n1-c1ccccc1 | Launched | true | ACH-000990 |
BRD-K60997853-001-02-3 | ACH-000990 | HEC108_ENDOMETRIUM | MTS010 | 1 | 0.238182 | 0.786957 | 0.72558 | 0.786015 | 0.763085 | 1.736233 | PHA-848125 | CDK inhibitor, growth factor receptor inhibitor | CDK2, CDK4, CDK7, NTRK1 | null | null | CNC(=O)c1nn(C)c-2c1C(C)(C)Cc1cnc(Nc3ccc(cc3)N3CCN(C)CC3)nc-21 | Phase 2 | true | ACH-000990 |
BRD-K61192372-001-08-9 | ACH-000990 | HEC108_ENDOMETRIUM | MTS010 | 1 | 0.745586 | -10.65058 | 0.373544 | 0.764869 | 4.792681 | null | capecitabine | DNA synthesis inhibitor, thymidylate synthase inhibitor | TYMS | oncology | breast cancer, colorectal cancer | CCCCCOC(=O)Nc1nc(=O)n(cc1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O, CCCCCOC(=O)Nc1nc(=O)n(cc1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O, CCCCCOC(=O)Nc1nc(=O)n(cc1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O, CCCCCOC(=O)Nc1nc(=O)n(cc1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O | Launched | true | ACH-000990 |
BRD-K62008436-001-23-9 | ACH-000990 | HEC108_ENDOMETRIUM | MTS010 | 1 | 0.75584 | 3.22156 | 0.106061 | 0.904878 | 0.014249 | null | paclitaxel | tubulin polymerization inhibitor | BCL2, MAP2, MAP4, MAPT, NR1I2, TLR4, TUBB, TUBB1 | oncology | ovarian cancer, breast cancer, non-small cell lung cancer (NSCLC) | CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1, CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1, CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1, CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1, CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1 | Launched | true | ACH-000990 |
BRD-K62196610-001-01-6 | ACH-000990 | HEC108_ENDOMETRIUM | MTS010 | 1 | 0.839529 | 0.133176 | -0.001722 | 0.919471 | 0.073786 | null | AVN-944 | inosine monophosphate dehydrogenase inhibitor | IMPDH1, IMPDH2 | null | null | CC[C@H](CC#N)OC(=O)N[C@@H](C)c1cccc(NC(=O)Nc2ccc(-c3cnco3)c(OC)c2)c1 | Phase 2 | true | ACH-000990 |
BRD-K62200014-003-10-5 | ACH-000990 | HEC108_ENDOMETRIUM | MTS010 | 1 | 0.690634 | -2.516451 | 0.539422 | 0.93914 | 0.004102 | null | anagrelide | phosphodiesterase inhibitor | PDE3A | hematology, hematologic malignancy | thrombocythemia, myeloproliferative neoplasms | Clc1ccc2N=C3NC(=O)CN3Cc2c1Cl, Clc1ccc2N=C3NC(=O)CN3Cc2c1Cl, Clc1ccc2N=C3NC(=O)CN3Cc2c1Cl | Launched | true | ACH-000990 |
BRD-K62391742-001-09-7 | ACH-000990 | HEC108_ENDOMETRIUM | MTS010 | 1 | 1.299934 | 0.052432 | 0.054582 | 1 | 0.05182 | null | venetoclax | BCL inhibitor | BCL2 | hematologic malignancy | chronic lymphocytic leukemia (CLL) | CC1(C)CCC(CN2CCN(CC2)c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c(c3)[N+]([O-])=O)c(Oc3cnc4[nH]ccc4c3)c2)=C(C1)c1ccc(Cl)cc1, CC1(C)CCC(CN2CCN(CC2)c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c(c3)[N+]([O-])=O)c(Oc3cnc4[nH]ccc4c3)c2)=C(C1)c1ccc(Cl)cc1, CC1(C)CCC(CN2CCN(CC2)c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c(c3)[N+]([O-])=O)c(Oc3cnc4[nH]ccc4c3)c2)=C(C1)c1ccc(Cl)cc1 | Launched | true | ACH-000990 |
BRD-K62627508-001-01-5 | ACH-000990 | HEC108_ENDOMETRIUM | MTS010 | 1 | 0.545501 | -0.074091 | -0.011258 | 0.822174 | 0.000188 | null | idasanutlin | MDM inhibitor | MDM2, TP53 | null | null | COc1cc(ccc1NC(=O)[C@@H]1N[C@@H](CC(C)(C)C)[C@@](C#N)([C@H]1c1cccc(Cl)c1F)c1ccc(Cl)cc1F)C(O)=O | Phase 3 | true | ACH-000990 |
BRD-K63504947-001-14-7 | ACH-000990 | HEC108_ENDOMETRIUM | MTS010 | 1 | 1.089207 | -0.175398 | -0.024408 | 1 | 5.95378 | null | semaxanib | VEGFR inhibitor | FGFR1, FLT1, KDR, KIT, PDGFRA, PDGFRB, RET | null | null | Cc1cc(C)c(\C=C2/C(=O)Nc3ccccc23)[nH]1, Cc1cc(C)c(\C=C2/C(=O)Nc3ccccc23)[nH]1, Cc1cc(C)c(\C=C2/C(=O)Nc3ccccc23)[nH]1, Cc1cc(C)c(\C=C2/C(=O)Nc3ccccc23)[nH]1 | Phase 3 | true | ACH-000990 |
BRD-K63712959-001-01-8 | ACH-000990 | HEC108_ENDOMETRIUM | MTS010 | 1 | 1.37487 | 2.099715 | 0.214453 | 1 | 1.417349 | null | temoporfin | radical formation stimulant | null | oncology | head and neck squamous cell carcinoma (HNSCC) | Oc1cccc(c1)-c1c2CCc(n2)c(-c2cccc(O)c2)c2ccc([nH]2)c(-c2cccc(O)c2)c2ccc(n2)c(-c2cccc(O)c2)c2ccc1[nH]2 | Launched | true | ACH-000990 |
BRD-K64881305-001-03-7 | ACH-000990 | HEC108_ENDOMETRIUM | MTS010 | 1 | 1.175161 | -0.224174 | -0.086829 | 1 | 0.03143 | null | ispinesib | kinesin inhibitor | KIF11 | null | null | CC(C)[C@@H](N(CCCN)C(=O)c1ccc(C)cc1)c1nc2cc(Cl)ccc2c(=O)n1Cc1ccccc1, CC(C)[C@@H](N(CCCN)C(=O)c1ccc(C)cc1)c1nc2cc(Cl)ccc2c(=O)n1Cc1ccccc1, CC(C)[C@@H](N(CCCN)C(=O)c1ccc(C)cc1)c1nc2cc(Cl)ccc2c(=O)n1Cc1ccccc1 | Phase 2 | true | ACH-000990 |
BRD-K66175015-001-12-4 | ACH-000990 | HEC108_ENDOMETRIUM | MTS010 | 1 | -0.922964 | 0.623268 | 0.473248 | 0.804634 | 12.918596 | 2.412335 | afatinib | EGFR inhibitor | EGFR, ERBB2, ERBB4 | oncology | non-small cell lung cancer (NSCLC) | CN(C)C\C=C\C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1, CN(C)C\C=C\C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1, CN(C)C\C=C\C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1 | Launched | true | ACH-000990 |
BRD-K67844266-003-01-9 | ACH-000990 | HEC108_ENDOMETRIUM | MTS010 | 1 | 0.981723 | -0.077279 | 0.000759 | 0.98919 | 9.905443 | null | pevonedistat | nedd activating enzyme inhibitor | NAE1, UBA3 | null | null | NS(=O)(=O)OC[C@@H]1C[C@H](C[C@@H]1O)n1ccc2c(N[C@H]3CCc4ccccc34)ncnc12 | Phase 2 | true | ACH-000990 |
BRD-K69001009-001-02-8 | ACH-000990 | HEC108_ENDOMETRIUM | MTS010 | 1 | 0.734929 | -2.412871 | 0.394227 | 0.895025 | 0.028473 | null | golvatinib | VEGFR inhibitor | KDR, MET | null | null | CN1CCN(CC1)C1CCN(CC1)C(=O)Nc1cc(Oc2ccc(NC(=O)C3(CC3)C(=O)Nc3ccc(F)cc3)c(F)c2)ccn1 | Phase 2 | true | ACH-000990 |
BRD-K69694239-001-02-2 | ACH-000990 | HEC108_ENDOMETRIUM | MTS010 | 1 | 0.223732 | 4.36464 | 0.654428 | 0.802185 | 0.843304 | 0.966081 | bardoxolone-methyl | nuclear factor erythroid derived, like (NRF2) activator | PPARG, STAT3 | null | null | COC(=O)[C@]12CCC(C)(C)C[C@H]1[C@H]1C(=O)C=C3[C@@]4(C)C=C(C#N)C(=O)C(C)(C)[C@@H]4CC[C@@]3(C)[C@]1(C)CC2 | Phase 3 | true | ACH-000990 |
BRD-K69776681-001-03-8 | ACH-000990 | HEC108_ENDOMETRIUM | MTS010 | 1 | 1.204162 | 2.872024 | 0.225215 | 1 | 0.007855 | null | volasertib | PLK inhibitor | PLK1 | null | null | CC[C@H]1N(C(C)C)c2nc(Nc3ccc(cc3OC)C(=O)N[C@H]3CC[C@@H](CC3)N3CCN(CC4CC4)CC3)ncc2N(C)C1=O, CC[C@H]1N(C(C)C)c2nc(Nc3ccc(cc3OC)C(=O)N[C@H]3CC[C@@H](CC3)N3CCN(CC4CC4)CC3)ncc2N(C)C1=O | Phase 3 | true | ACH-000990 |
BRD-K70301465-001-05-9 | ACH-000990 | HEC108_ENDOMETRIUM | MTS010 | 1 | 0.774102 | 0.134525 | 0.005224 | 0.909857 | 1.821782 | null | ibrutinib | Bruton's tyrosine kinase (BTK) inhibitor | BLK, BMX, BTK | hematologic malignancy | chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), Waldenstrom's macroglobulinemia (WM) | Nc1ncnc2n(nc(-c3ccc(Oc4ccccc4)cc3)c12)[C@@H]1CCCN(C1)C(=O)C=C, Nc1ncnc2n(nc(-c3ccc(Oc4ccccc4)cc3)c12)[C@@H]1CCCN(C1)C(=O)C=C | Launched | true | ACH-000990 |
BRD-K70401845-001-15-7 | ACH-000990 | HEC108_ENDOMETRIUM | MTS010 | 1 | 0.817904 | 3.059058 | 0.10696 | 0.892663 | 0.032783 | null | erlotinib | EGFR inhibitor | EGFR, NR1I2 | oncology | non-small cell lung cancer (NSCLC), pancreatic cancer | COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC, COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC | Launched | true | ACH-000990 |
BRD-K73838513-003-05-5 | ACH-000990 | HEC108_ENDOMETRIUM | MTS010 | 1 | 0.942051 | -0.006172 | -0.041464 | 0.966893 | 12,628,249,252,992,858,000 | null | cinacalcet | calcium channel activator | CASR | endocrinology, nephrology, oncology | hyperparathyroidism, chronic kidney disease (CKD), parathyroid carcinoma, hypercalcemia | C[C@@H](NCCCc1cccc(c1)C(F)(F)F)c1cccc2ccccc12 | Launched | true | ACH-000990 |
BRD-K74514084-003-09-2 | ACH-000990 | HEC108_ENDOMETRIUM | MTS010 | 1 | 0.461424 | 0.065784 | -0.023721 | 0.871988 | 4,417,242.537577 | null | pazopanib | KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor | CSF1R, FGF1, FGFR1, FGFR3, FLT1, FLT4, ITK, KDR, KIT, PDGFRA, PDGFRB, SH2B3 | oncology | renal cell carcinoma (RCC), soft tissue sarcoma (STS) | CN(c1ccc2c(C)n(C)nc2c1)c1ccnc(Nc2ccc(C)c(c2)S(N)(=O)=O)n1, CN(c1ccc2c(C)n(C)nc2c1)c1ccnc(Nc2ccc(C)c(c2)S(N)(=O)=O)n1 | Launched | true | ACH-000990 |
BRD-K75009076-001-02-1 | ACH-000990 | HEC108_ENDOMETRIUM | MTS010 | 1 | -0.019581 | 1.755579 | 0.625033 | 0.870041 | 3.109765 | 3.042452 | SCH-900776 | CHK inhibitor | CDK2, CHEK1 | null | null | Cn1cc(cn1)-c1cnn2c(N)c(Br)c(nc12)[C@@H]1CCCNC1, Cn1cc(cn1)-c1cnn2c(N)c(Br)c(nc12)[C@@H]1CCCNC1 | Phase 2 | true | ACH-000990 |
BRD-K76210423-001-01-6 | ACH-000990 | HEC108_ENDOMETRIUM | MTS010 | 1 | 1.126187 | 4.05121 | -0.073966 | 1 | 0.047139 | null | resiquimod | toll-like receptor agonist | TLR7, TLR8 | null | null | CCOCc1nc2c(N)nc3ccccc3c2n1CC(C)(C)O, CCOCc1nc2c(N)nc3ccccc3c2n1CC(C)(C)O | Phase 3 | true | ACH-000990 |
BRD-K76239644-001-02-6 | ACH-000990 | HEC108_ENDOMETRIUM | MTS010 | 1 | 0.466005 | 5.663687 | 0.559878 | 0.818536 | 0.36962 | 0.594158 | BMS-690514 | EGFR inhibitor, VEGFR inhibitor | EGFR, ERBB2, FLT3, KDR | null | null | COc1cccc(Nc2ncnn3ccc(CN4CC[C@@H](N)[C@H](O)C4)c23)c1, COc1cccc(Nc2ncnn3ccc(CN4CC[C@@H](N)[C@H](O)C4)c23)c1 | Phase 2 | true | ACH-000990 |
BRD-K76674262-001-03-3 | ACH-000990 | HEC108_ENDOMETRIUM | MTS010 | 1 | 0.124514 | 12.389749 | 0.906403 | 0.732691 | 0.516597 | 0.528675 | homoharringtonine | protein synthesis inhibitor | RPL3 | hematologic malignancy | chronic myeloid leukemia (CML) | COC(=O)C[C@](O)(CCCC(C)(C)O)C(=O)O[C@H]1[C@H]2c3cc4OCOc4cc3CCN3CCC[C@]23C=C1OC | Launched | true | ACH-000990 |
BRD-K76908866-001-07-6 | ACH-000990 | HEC108_ENDOMETRIUM | MTS010 | 1 | 0.863998 | -0.22199 | 0.004569 | 0.928886 | 0.122714 | null | CP-724714 | EGFR inhibitor, protein tyrosine kinase inhibitor | ERBB2 | null | null | COCC(=O)NC\C=C\c1ccc2ncnc(Nc3ccc(Oc4ccc(C)nc4)c(C)c3)c2c1 | Phase 2 | true | ACH-000990 |
BRD-K77625799-001-07-7 | ACH-000990 | HEC108_ENDOMETRIUM | MTS010 | 1 | 0.751733 | 0.233257 | 0.126306 | 0.896086 | 0.369866 | null | vandetanib | EGFR inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor | EGFR, EPHA1, EPHA10, EPHA2, EPHA3, EPHA4, EPHA5, EPHA6, EPHA7, EPHA8, EPHB1, EPHB2, EPHB3, EPHB4, EPHB6, ERBB2, ERBB3, ERBB4, FLT1, FLT4, KDR, PTK6, RET, SRC, TEK, VEGFA | oncology | medullary thyroid cancer (MTC) | COc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCC1CCN(C)CC1 | Launched | true | ACH-000990 |
BRD-K78431006-001-15-1 | ACH-000990 | HEC108_ENDOMETRIUM | MTS010 | 1 | 0.888182 | -0.094597 | -0.039651 | 0.929838 | 21.240283 | null | crizotinib | ALK tyrosine kinase receptor inhibitor | ALK, MET | oncology | non-small cell lung cancer (NSCLC) | C[C@@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl, C[C@@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl, C[C@@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl | Launched | true | ACH-000990 |
BRD-K79254416-001-21-8 | ACH-000990 | HEC108_ENDOMETRIUM | MTS010 | 1 | -0.114746 | 0.558032 | 0.071896 | 0.944033 | 79.58398 | null | decitabine | DNA methyltransferase inhibitor | DNMT1, DNMT3A | hematologic malignancy, hematology | myelodysplastic diseases (MDS), anemia, chronic myeloid leukemia (CML) | Nc1ncn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1, Nc1ncn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1, Nc1ncn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1 | Launched | true | ACH-000990 |
BRD-K81016934-001-02-0 | ACH-000990 | HEC108_ENDOMETRIUM | MTS010 | 1 | 0.792388 | 1.091487 | 0.135735 | 0.838721 | 0.004861 | null | INC-280 | c-Met inhibitor | MET | null | null | CNC(=O)c1ccc(cc1F)-c1cnc2ncc(Cc3ccc4ncccc4c3)n2n1 | Phase 2 | true | ACH-000990 |
BRD-K81418486-001-44-2 | ACH-000990 | HEC108_ENDOMETRIUM | MTS010 | 1 | 0.732879 | 2.278058 | 0.052125 | 0.920792 | 0.563013 | null | vorinostat | HDAC inhibitor | HDAC1, HDAC10, HDAC11, HDAC2, HDAC3, HDAC5, HDAC6, HDAC8, HDAC9 | hematologic malignancy | cutaneous T-cell lymphoma (CTCL) | ONC(=O)CCCCCCC(=O)Nc1ccccc1, ONC(=O)CCCCCCC(=O)Nc1ccccc1, ONC(=O)CCCCCCC(=O)Nc1ccccc1 | Launched | true | ACH-000990 |
BRD-K81473043-001-19-5 | ACH-000990 | HEC108_ENDOMETRIUM | MTS010 | 1 | 2.284258 | 0.694239 | 0.362948 | 1 | 0.500803 | null | tanespimycin | HSP inhibitor | HSP90AA1 | null | null | CO[C@H]1C[C@H](C)CC2=C(NCC=C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O, CO[C@H]1C[C@H](C)CC2=C(NCC=C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O | Phase 3 | true | ACH-000990 |
BRD-K82135108-001-04-3 | ACH-000990 | HEC108_ENDOMETRIUM | MTS010 | 1 | 1.167208 | 0.075153 | -0.002798 | 1 | 0.030959 | null | elesclomol | oxidative stress inducer | HSPA1A | null | null | CN(NC(=O)CC(=O)NN(C)C(=S)c1ccccc1)C(=S)c1ccccc1 | Phase 3 | true | ACH-000990 |
BRD-K82746043-001-19-3 | ACH-000990 | HEC108_ENDOMETRIUM | MTS010 | 1 | 0.240437 | 1.92007 | 0.705122 | 0.557256 | 0.034931 | 0.049148 | navitoclax | BCL inhibitor | BCL2, BCL2L1, BCL2L2 | null | null | CC1(C)CCC(=C(CN2CCN(CC2)c2ccc(cc2)C(=O)NS(=O)(=O)c2ccc(N[C@H](CCN3CCOCC3)CSc3ccccc3)c(c2)S(=O)(=O)C(F)(F)F)C1)c1ccc(Cl)cc1, CC1(C)CCC(=C(CN2CCN(CC2)c2ccc(cc2)C(=O)NS(=O)(=O)c2ccc(N[C@H](CCN3CCOCC3)CSc3ccccc3)c(c2)S(=O)(=O)C(F)(F)F)C1)c1ccc(Cl)cc1 | Phase 2 | true | ACH-000990 |
BRD-K82818427-001-04-8 | ACH-000990 | HEC108_ENDOMETRIUM | MTS010 | 1 | 0.60139 | 0.572634 | 0.414917 | 0.782849 | 0.047716 | null | batimastat | matrix metalloprotease inhibitor | ADAM28, ADAMTS5, MMP12, MMP16, MMP2, MMP8 | null | null | CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)[C@H](CSc1cccs1)C(=O)NO, CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)[C@H](CSc1cccs1)C(=O)NO | Phase 3 | true | ACH-000990 |
BRD-K83029223-001-01-3 | ACH-000990 | HEC108_ENDOMETRIUM | MTS010 | 1 | 0.805283 | 7.25125 | 0.337895 | 0.902226 | 0.00478 | null | litronesib | kinesin-like spindle protein inhibitor | KIF11 | null | null | CCNCCS(=O)(=O)NC[C@]1(SC(NC(=O)C(C)(C)C)=NN1C(=O)C(C)(C)C)c1ccccc1 | Phase 2 | true | ACH-000990 |
BRD-K83988098-001-02-0 | ACH-000990 | HEC108_ENDOMETRIUM | MTS010 | 1 | 0.731022 | -1.043848 | -0.107726 | 0.942767 | 0.000067 | null | alvespimycin | HSP inhibitor | HSP90AA1 | null | null | CO[C@H]1C[C@H](C)CC2=C(NCCN(C)C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O, CO[C@H]1C[C@H](C)CC2=C(NCCN(C)C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O | Phase 2 | true | ACH-000990 |
BRD-K85402309-043-01-9 | ACH-000990 | HEC108_ENDOMETRIUM | MTS010 | 1 | 0.857753 | -0.119944 | -0.127214 | 0.926775 | 0.064585 | null | dovitinib | EGFR inhibitor, FGFR inhibitor, FLT3 inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor | CSF1R, EGFR, FGFR1, FGFR2, FGFR3, FLT1, FLT3, FLT4, INSR, KDR, KIT, PDGFRA, PDGFRB | null | null | CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O | Phase 3 | true | ACH-000990 |
BRD-K86118762-001-01-8 | ACH-000990 | HEC108_ENDOMETRIUM | MTS010 | 1 | 1.009157 | -0.362368 | -0.186056 | 1 | 0.64997 | null | linsitinib | IGF-1 inhibitor | IGF1R, INSR, INSRR | null | null | C[C@@]1(O)C[C@@H](C1)c1nc(-c2ccc3ccc(nc3c2)-c2ccccc2)c2c(N)nccn12, C[C@@]1(O)C[C@@H](C1)c1nc(-c2ccc3ccc(nc3c2)-c2ccccc2)c2c(N)nccn12 | Phase 3 | true | ACH-000990 |
BRD-K86972824-001-01-4 | ACH-000990 | HEC108_ENDOMETRIUM | MTS010 | 1 | 0.894588 | -0.3391 | 0.065307 | 0.948522 | 0.066081 | null | oltipraz | nuclear factor erythroid derived, like (NRF2) activator | ANG | null | null | Cc1c(ssc1=S)-c1cnccn1, Cc1c(ssc1=S)-c1cnccn1 | Phase 3 | true | ACH-000990 |
BRD-K87737963-001-06-0 | ACH-000990 | HEC108_ENDOMETRIUM | MTS010 | 1 | 0.702321 | -1.532545 | 0.228344 | 0.956103 | 0.002362 | null | cyt387 | null | JAK1, JAK2, JAK3 | null | null | O=C(NCC#N)c1ccc(cc1)-c1ccnc(Nc2ccc(cc2)N2CCOCC2)n1, O=C(NCC#N)c1ccc(cc1)-c1ccnc(Nc2ccc(cc2)N2CCOCC2)n1 | Phase 3 | true | ACH-000990 |
BRD-K87782578-001-01-4 | ACH-000990 | HEC108_ENDOMETRIUM | MTS010 | 1 | 0.726248 | 0.958723 | 0.115901 | 0.884146 | 0.167155 | null | AVL-292 | Bruton's tyrosine kinase (BTK) inhibitor | BTK, YES1 | null | null | COCCOc1ccc(Nc2ncc(F)c(Nc3cccc(NC(=O)C=C)c3)n2)cc1 | Phase 2 | true | ACH-000990 |
BRD-K87909389-003-03-4 | ACH-000990 | HEC108_ENDOMETRIUM | MTS010 | 1 | 0.226817 | 3.963534 | 0.736346 | 0.726124 | 0.321428 | 0.374384 | alvocidib | CDK inhibitor | CDK1, CDK2, CDK4, CDK5, CDK6, CDK7, CDK8, CDK9, EGFR, PYGM | null | null | CN1CC[C@@H]([C@H](O)C1)c1c(O)cc(O)c2c1oc(cc2=O)-c1ccccc1Cl, CN1CC[C@@H]([C@H](O)C1)c1c(O)cc(O)c2c1oc(cc2=O)-c1ccccc1Cl | Phase 2 | true | ACH-000990 |
BRD-K88510285-001-17-8 | ACH-000990 | HEC108_ENDOMETRIUM | MTS010 | 1 | 0.125289 | 7.067947 | 0.782495 | 0.611815 | 0.033741 | 0.035146 | bortezomib | NFkB pathway inhibitor, proteasome inhibitor | PSMA1, PSMA2, PSMA3, PSMA4, PSMA5, PSMA6, PSMA7, PSMA8, PSMB1, PSMB10, PSMB11, PSMB2, PSMB3, PSMB4, PSMB5, PSMB6, PSMB7, PSMB8, PSMB9, PSMD1, PSMD2, RELA | hematologic malignancy | multiple myeloma, mantle cell lymphoma (MCL) | CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O | Launched | true | ACH-000990 |
BRD-K89014967-001-04-3 | ACH-000990 | HEC108_ENDOMETRIUM | MTS010 | 1 | 0.678855 | -2.301994 | 0.223235 | 0.739861 | 1.592566 | null | AS-703026 | MEK inhibitor | MAP2K1, MAP2K2 | null | null | OC[C@@H](O)CNC(=O)c1ccncc1Nc1ccc(I)cc1F | Phase 2 | true | ACH-000990 |
BRD-K92441787-001-04-1 | ACH-000990 | HEC108_ENDOMETRIUM | MTS010 | 1 | 0.886028 | -3.516909 | 0.095123 | 0.93446 | 0.161802 | null | bexarotene | retinoid receptor agonist | RXRA, RXRB, RXRG | hematologic malignancy | cutaneous T-cell lymphoma (CTCL) | Cc1cc2c(cc1C(=C)c1ccc(cc1)C(O)=O)C(C)(C)CCC2(C)C | Launched | true | ACH-000990 |
BRD-K92723993-001-17-4 | ACH-000990 | HEC108_ENDOMETRIUM | MTS010 | 1 | 0.998797 | -0.014552 | -0.000176 | 0.999409 | 0.006544 | null | imatinib | Bcr-Abl kinase inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor | ABL1, CSF1R, DDR1, KIT, NTRK1, PDGFRA, PDGFRB, RET | hematologic malignancy, oncology | chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL), myelodysplastic diseases (MDS), aggressive systemic mastocytosis (ASM), hypereosinophilic syndrome (HES), chronic eosinophilic leukemia (CEL), dermatofibrosarcoma protuberans (DFSP), gastrointestinal stromal tumors (GIST) | CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1, CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1, CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1 | Launched | true | ACH-000990 |
BRD-K95142244-001-01-5 | ACH-000990 | HEC108_ENDOMETRIUM | MTS010 | 1 | 1.027884 | -0.04108 | -0.183062 | 1 | 2.493485 | null | talazoparib | PARP inhibitor | PARP2 | null | null | Cn1ncnc1[C@@H]1[C@H](Nc2cc(F)cc3c2c1n[nH]c3=O)c1ccc(F)cc1 | Phase 3 | true | ACH-000990 |
BRD-K96123349-236-02-8 | ACH-000990 | HEC108_ENDOMETRIUM | MTS010 | 1 | 1.155879 | 0.030643 | -0.005754 | 1 | 0.00055 | null | brequinar | dihydroorotate dehydrogenase inhibitor | DHODH | null | null | Cc1c(nc2ccc(F)cc2c1C(O)=O)-c1ccc(cc1)-c1ccccc1F | Phase 2 | true | ACH-000990 |
BRD-K98572433-001-02-9 | ACH-000990 | HEC108_ENDOMETRIUM | MTS010 | 1 | 0.937742 | 0.513878 | 0.001958 | 0.963258 | 0.02762 | null | AZD8931 | EGFR inhibitor | EGFR, ERBB2, ERBB3 | null | null | CNC(=O)CN1CCC(CC1)Oc1cc2c(Nc3cccc(Cl)c3F)ncnc2cc1OC | Phase 2 | true | ACH-000990 |
BRD-K99113996-001-02-0 | ACH-000990 | HEC108_ENDOMETRIUM | MTS010 | 1 | 0.495464 | 0.592693 | 0.362079 | 0.781374 | 0.161533 | null | AZD2014 | mTOR inhibitor | MTOR | null | null | CNC(=O)c1cccc(c1)-c1ccc2c(nc(nc2n1)N1CCOC[C@@H]1C)N1CCOC[C@@H]1C | Phase 2 | true | ACH-000990 |
BRD-K99616396-001-05-1 | ACH-000990 | HEC108_ENDOMETRIUM | MTS010 | 1 | 0.916827 | -2.625369 | -0.063491 | 0.934337 | 1.298586 | null | motesanib | KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor | FLT1, FLT4, KDR, KIT | null | null | CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12, CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12, CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12, CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12, CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12 | Phase 3 | true | ACH-000990 |
BRD-K99749624-001-07-0 | ACH-000990 | HEC108_ENDOMETRIUM | MTS010 | 1 | 1.397977 | 1.441092 | 0.791615 | 1 | 0.146792 | null | linifanib | PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor | CSF1, CSF1R, FLT1, FLT3, FLT4, KDR, KIT, PDGFRB, RET, TEK | null | null | Cc1ccc(F)c(NC(=O)Nc2ccc(cc2)-c2cccc3[nH]nc(N)c23)c1 | Phase 3 | true | ACH-000990 |
BRD-M97302542-001-04-4 | ACH-000990 | HEC108_ENDOMETRIUM | MTS010 | 1 | 1.047133 | 0.067101 | -0.069985 | 1 | 0.513349 | null | dichloroacetate | pyruvate dehydrogenase kinase inhibitor | PDK1 | null | null | [Na].OC(=O)C(Cl)Cl, [Na].OC(=O)C(Cl)Cl | Phase 3 | true | ACH-000990 |
BRD-A25234499-001-19-1 | ACH-000991 | SNU81_LARGE_INTESTINE | MTS010 | 1 | 1.036537 | -0.114854 | -0.096474 | 1 | 1.044944 | null | aminoglutethimide | glucocorticoid receptor antagonist | CYP11A1, CYP19A1 | endocrinology, oncology | Cushing's syndrome, breast cancer | CCC1(CCC(=O)NC1=O)c1ccc(N)cc1, CCC1(CCC(=O)NC1=O)c1ccc(N)cc1, CCC1(CCC(=O)NC1=O)c1ccc(N)cc1 | Launched | true | ACH-000991 |
BRD-A70858459-001-01-7 | ACH-000991 | SNU81_LARGE_INTESTINE | MTS010 | 1 | 0.729595 | 0.02189 | -0.152579 | 0.920398 | 17,875,370,086,010,278 | null | estramustine | DNA alkylating agent | ESR1, ESR2, MAP1A, MAP2 | oncology | prostate cancer | C[C@]12CCC3C(CCc4cc(OC(=O)N(CCCl)CCCl)ccc34)C1CC[C@@H]2O | Launched | true | ACH-000991 |
BRD-K02113016-001-19-6 | ACH-000991 | SNU81_LARGE_INTESTINE | MTS010 | 1 | 0.558478 | 0.083913 | -0.011818 | 0.720624 | 0.000109 | null | olaparib | PARP inhibitor | PARP1, PARP2 | oncology | ovarian cancer | Fc1ccc(Cc2n[nH]c(=O)c3ccccc23)cc1C(=O)N1CCN(CC1)C(=O)C1CC1, Fc1ccc(Cc2n[nH]c(=O)c3ccccc23)cc1C(=O)N1CCN(CC1)C(=O)C1CC1 | Launched | true | ACH-000991 |
BRD-K02130563-001-11-4 | ACH-000991 | SNU81_LARGE_INTESTINE | MTS010 | 1 | 0.229254 | 4.680042 | 0.482867 | 0.697456 | 0.221614 | 0.252652 | panobinostat | HDAC inhibitor | HDAC1, HDAC2, HDAC3, HDAC4, HDAC6, HDAC7, HDAC8, HDAC9 | hematologic malignancy | multiple myeloma | Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1, Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1, Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1, Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1 | Launched | true | ACH-000991 |
BRD-K03390685-001-01-7 | ACH-000991 | SNU81_LARGE_INTESTINE | MTS010 | 1 | 0.753907 | 0.428311 | 0.099297 | 0.913276 | 0.512964 | null | cobimetinib | MEK inhibitor | null | oncology | melanoma | OC1(CN(C1)C(=O)c1ccc(F)c(F)c1Nc1ccc(I)cc1F)[C@@H]1CCCCN1 | Launched | true | ACH-000991 |
BRD-K03406345-001-21-1 | ACH-000991 | SNU81_LARGE_INTESTINE | MTS010 | 1 | 0.835617 | -0.060919 | -0.090006 | 0.887338 | 30,294.523544 | null | azacitidine | DNA methyltransferase inhibitor | DNMT1, DNMT3A | hematologic malignancy, hematology | myelodysplastic diseases (MDS), anemia, chronic myelomonocytic leukemia (CMMoL) | Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000991 |
BRD-K03449891-001-08-6 | ACH-000991 | SNU81_LARGE_INTESTINE | MTS010 | 1 | 0.73183 | 1.055023 | -0.181824 | 0.807823 | 0.00905 | null | foretinib | VEGFR inhibitor | FLT1, FLT4, KDR, MET | null | null | COc1cc2c(Oc3ccc(NC(=O)C4(CC4)C(=O)Nc4ccc(F)cc4)cc3F)ccnc2cc1OCCCN1CCOCC1 | Phase 2 | true | ACH-000991 |
BRD-K03765900-001-01-9 | ACH-000991 | SNU81_LARGE_INTESTINE | MTS010 | 1 | 1.00306 | -0.196754 | -0.04606 | 1 | 0.220711 | null | XL-647 | EGFR inhibitor, VEGFR inhibitor | EGFR, EPHB4, ERBB2, FLT4, KDR | null | null | COc1cc2c(Nc3ccc(Cl)c(Cl)c3F)ncnc2cc1OC[C@H]1C[C@H]2CN(C)C[C@H]2C1 | Phase 3 | true | ACH-000991 |
BRD-K05804044-001-18-5 | ACH-000991 | SNU81_LARGE_INTESTINE | MTS010 | 1 | 1.849071 | 1.056891 | 0.143304 | 1 | 4.82263 | null | AZ-628 | RAF inhibitor | BRAF, RAF1 | null | null | Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1 | Preclinical | true | ACH-000991 |
BRD-K06814349-304-02-7 | ACH-000991 | SNU81_LARGE_INTESTINE | MTS010 | 1 | 0.512132 | 2.796531 | 0.369954 | 0.875099 | 0.833933 | null | fosbretabulin | tubulin polymerization inhibitor, VE-cadherin antagonist | CDH5 | null | null | COc1ccc(C=Cc2cc(OC)c(OC)c(OC)c2)cc1OP(O)(O)=O, COc1ccc(cc1OP(O)(O)=O)\C=C/c1cc(OC)c(OC)c(OC)c1, COc1ccc(cc1OP(O)(O)=O)\C=C/c1cc(OC)c(OC)c(OC)c1, COc1ccc(C=Cc2cc(OC)c(OC)c(OC)c2)cc1OP(O)(O)=O | Phase 3 | true | ACH-000991 |
BRD-K08109215-001-06-4 | ACH-000991 | SNU81_LARGE_INTESTINE | MTS010 | 1 | 0.807686 | 2.652683 | -0.081243 | 0.881374 | 0.025132 | null | I-BET-762 | bromodomain inhibitor | BRD2, BRD3, BRD4 | null | null | CCNC(=O)C[C@@H]1N=C(c2ccc(Cl)cc2)c2cc(OC)ccc2-n2c(C)nnc12 | Phase 2 | true | ACH-000991 |
BRD-K08542803-001-02-3 | ACH-000991 | SNU81_LARGE_INTESTINE | MTS010 | 1 | 0.90164 | -1.55031 | -0.043506 | 0.960647 | 0.029575 | null | gambogic-acid | caspase activator | BCL2 | null | null | CC(C)=CCC[C@@]1(C)Oc2c(CC=C(C)C)c3O[C@@]45[C@H]6C[C@@H](C=C4C(=O)c3c(O)c2C=C1)C(=O)[C@]5(C\C=C(\C)C(O)=O)OC6(C)C, CC(C)=CCC[C@@]1(C)Oc2c(CC=C(C)C)c3O[C@@]45[C@H]6C[C@@H](C=C4C(=O)c3c(O)c2C=C1)C(=O)[C@]5(C\C=C(\C)C(O)=O)OC6(C)C, CC(C)=CCC[C@@]1(C)Oc2c(CC=C(C)C)c3O[C@@]45[C@H]6C[C@@H](C=C4C(=O)c3c(O)c2C=C1)C(=O)[C@]5(C\C=C(\C)C(O)=O)OC6(C)C | Phase 2 | true | ACH-000991 |
BRD-K08547377-001-04-4 | ACH-000991 | SNU81_LARGE_INTESTINE | MTS010 | 1 | 0.768604 | 0.143299 | -0.099489 | 0.847118 | 0.000624 | null | irinotecan | topoisomerase inhibitor | TOP1, TOP1MT | oncology | colorectal cancer | CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12 | Launched | true | ACH-000991 |
BRD-K08703257-001-13-9 | ACH-000991 | SNU81_LARGE_INTESTINE | MTS010 | 1 | 0.954939 | -0.138575 | 0.00379 | 0.977439 | 0.079664 | null | 3-amino-benzamide | PARP inhibitor | PARP1 | null | null | NC(=O)c1cccc(N)c1, NC(=O)c1cccc(N)c1 | Phase 2 | true | ACH-000991 |
BRD-K08799216-001-05-3 | ACH-000991 | SNU81_LARGE_INTESTINE | MTS010 | 1 | 1.442116 | -0.292387 | 0.010204 | 1 | 0.072147 | null | pelitinib | EGFR inhibitor | EGFR | null | null | CCOc1cc2ncc(C#N)c(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)\C=C\CN(C)C | Phase 2 | true | ACH-000991 |
Subsets and Splits
No saved queries yet
Save your SQL queries to embed, download, and access them later. Queries will appear here once saved.